Noor Jehanzeb 4

What Happened Noor Jehanzeb, Senior Vice President, Chief Strategy, Innovation & Business Development Officer at Zimmer Biomet (ZBH), had one-third of a grant of restricted stock units (RSUs) vest on April 1, 2026. The vesting resulted in 6,626 shares credited (conversion of RSUs to common stock). To cover tax withholding on the vesting, 1,677 shares were surrendered to the company at an implied withholding price of $90.67 per share (value withheld = $152,054), leaving a net 4,949 shares delivered to Jehanzeb. The filing shows the RSU conversion as a derivative exercise (code M) and the withholding as a tax payment/disposition (code F).

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (timely).
• Vesting/conversion: 6,626 RSUs converted to 6,626 shares (code M).
• Tax withholding: 1,677 shares withheld at $90.67 each = $152,054 (code F).
• Net shares received: 6,626 – 1,677 = 4,949 shares.
• Footnotes: F1 notes 202 shares from the Employee Stock Purchase Plan (Dec 31, 2025); F2–F4 confirm shares were withheld to satisfy tax withholding and describe RSU vesting schedule (one‑third vested Apr 1, 2026; remaining vest in 2027–2028).
• Shares owned after transaction: Not specified in this Form 4 (or not provided in the summary data).

Context

• This was a routine vesting/settlement of RSUs, not an open‑market purchase or discretionary sale; withholding shares to cover taxes is a standard, non‑indicative practice.
• The filing shows both the derivative conversion (RSU → shares) and the withholding disposition; this is common when awards settle into stock and the company retains shares for taxes.
• No 10% owner, gift, or 10b5‑1 sale plan is indicated.